^18F-FDG和^18F—FLT PET—CT在肿瘤非手术治疗早期疗效评价中的应用

^18F-FDG and ^18F-FLT PET-CT in evaluation of the early response of malignant tumors after different therapies

早期监测肿瘤在不同治疗方法中的疗效已成为临床上亟待解决的问题。PET可从分子水平上观察细胞生物学行为，尤其是对肿瘤的早期诊断、分期及疗效评价具有较高的特异度。^18F-FDG为葡萄糖类代谢显像剂，作为目前应用最为广泛的显像剂，因其本身固有的一些特点表现为对肿瘤的非特异性显像。3’-脱氧．3＇-^18F-氟胸腺嘧啶（^18F-FLT）为核苷酸类代谢显像剂，在细胞增殖显像方面的应用较为广泛。两者在肿瘤监测、分期及疗效评价方面各具特点。该文就PET-CT在肿瘤疗效评价中的应用进行综述，同时探讨两者在监测非手术治疗疗效时何者更具有优势。

For the evaluation of the early effect of different therapies for the treatment of malignant tumors, reduction in tumor volume is the most commonly used criterion for efficacy. However, the time until tumor shrinkage can be long and it requires repeated tumor volume measurements several times weekly to show effect. Non-invasive method such as PET allows for biological processes to be visualized and quantified non-invasively over time, and it has a high specificity for the early diagnosis, staging and evaluate the response of tumors. ^18F-FDG is the most widely used radiotracer for imaging in oncology and is very useful for detecting and characterizing cancers currently. But it is not a tumor specific agent for the intrinsic property. 3＇-deoxy-3＇-＇SF- fluorothymidine （^18F-FLT） is used as a PET tracer for visualization of cell proliferation and it has become more widely used in clinic. Both of them have their own features in the diagnosis, staging and early detect response of tumors. This article reviewed the application of ^18F-FDG and ~SF-FLT to evaluate the early response of malignant tumors after different therapies. Besides, at the same time,^18F-FDG and ^18F-FLT which is more specific or superiority to measure early response of tumors after definite treatment was discussed.